Novavax needs 6 months to produce annual COVID shots that match new variants

Novavax needs 6 months to produce annual COVID shots that match new variants The company suggested that the US Food and Drug Administration select the prevalent variant of coronavirus in the first quarter of each year, similar to the model employed to choose the composition for annual flu shots. https://ift.tt/VkLUBGK

Insurance Bill may not be introduced in budget session

Insurance Bill may not be introduced in budget session The General Insurance Council, a grouping of non-life insurers, has opposed the composite licence, warning that letting companies enter any segment will result in chaos and fragmentation of existing markets, an industry executive told ET. https://ift.tt/VkLUBGK

World’s 1st COVID nasal vaccine by Bharat Biotech launched on R-Day

World’s 1st COVID nasal vaccine by Bharat Biotech launched on R-Day This vaccine has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries. As a needleless vaccination, Bharat Biotech's iNCOVACC will be the world's first such booster dose. India will now have more options when it comes to third doses or precautionary doses. https://ift.tt/VkLUBGK

A Musician and A Doctor made this customisable stethoscope, with Sound Filters and 100x Amplification

submitted by /u/smokeytheghost [link] [comments]

Roche launches new test to detect fast spreading Omicron sub-variant

The new test specifically targets the XBB.1.5 Omicron variant and will help researchers closely track the virus's lineage and provide insights into the epidemiology and impact it has on public health.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/reNUB3K
via gqrds

Roche launches new test to detect fast spreading Omicron sub-variant

Roche launches new test to detect fast spreading Omicron sub-variant The new test specifically targets the XBB.1.5 Omicron variant and will help researchers closely track the virus's lineage and provide insights into the epidemiology and impact it has on public health. https://ift.tt/aVnRsMp

Vaccine against cervical cancer to begin from June: Expert

The Pune-based vaccine major, Serum Institute of India (SII), launched the madein-India vaccine Cervavac on January 24. It will cost about Rs 150 per dose to the Union government and around Rs 300, Rs 350 in the private market, sources in the Union health ministry said. The imported version of the vaccine available in the private market costs about Rs 3,500 to Rs 4,000 per dose. SII officials, however, refused to comment on the pricing.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/uQfCsMv
via gqrds